Get the Daily Brief
Latest Biotech News
Cancer Vaccines: IO Biotech’s Narrow Miss in Melanoma Trial
IO Biotech’s off-the-shelf therapeutic cancer vaccine Cylembio narrowly missed its primary endpoint in a pivotal Phase 3 melanoma study, falling just short of statistical significance despite...
Expedition Therapeutics In-Licenses Fosun Lung Disease Drug
Expedition Therapeutics secured a licensing deal worth up to $645 million to develop and commercialize Fosun Pharma’s experimental DPP-1 inhibitor outside China, marking its first public drug...
Boehringer Ingelheim Scores FDA Nod for Lung Cancer Drug Hernexeos
Boehringer Ingelheim’s oral HER2-targeted therapy, Hernexeos (zongertinib), gained accelerated approval from the FDA for non-small cell lung cancer patients with specific HER2 activating...
AI Breakthroughs Advance Disease Diagnostics and Patient Care
Recent innovations harness artificial intelligence to transform medical diagnostics and emergency care. Researchers developed AI models that enable early detection of voice box cancer through...
Gene Editing Advances: Precision and Safety Enhancements
Groundbreaking research has enhanced genome editing precision through novel microhomology-based DNA template design guided by deep learning algorithms, improving targeted DNA integrations in...
Mitochondrial Activation Reverses Neurodegenerative Deficits in Models
A team from Inserm and Université de Bordeaux developed mitoDREADD-Gs, a mitochondria-targeted designer receptor that, when activated, enhances mitochondrial energy functions and reverses...
Breakthroughs in Cancer Therapy: Targeted Vaccines and Metabolic Drugs
Innovative cancer treatments show promise across multiple fronts. A peptide-based vaccine inducing immune responses against lymph node-resident cancer cells demonstrates encouraging results in...
Biotech Market Volatility and Leadership Shifts at FDA
Vinay Prasad has been reinstated as director of the FDA’s Center for Biologics Evaluation and Research (CBER) just two weeks after his ouster following political controversy. The return was...
Pfizer's Padcev Extends Survival in Bladder Cancer Combo
Pfizer announced that its antibody-drug conjugate Padcev, when combined with the immunotherapy Keytruda, significantly extended survival in patients with invasive bladder cancer who were...
Novartis Scores Dual Phase 3 Wins in Sjögren’s Syndrome
Novartis secured two successful Phase 3 trial results for ianalumab, an antibody targeting BAFF-R, in patients with Sjögren’s syndrome, a challenging autoimmune disorder. Both NEPTUNUS 1 and 2...
IO Biotech’s Cancer Vaccine Misses Primary Endpoint Narrowly
IO Biotech’s experimental cancer vaccine Cylembio, combined with Merck’s Keytruda, narrowly missed its primary endpoint of progression-free survival in a Phase 3 melanoma trial. Despite a hazard...
AI Enables Early Detection of Voice Box Cancer
Researchers have developed an AI-driven method analyzing acoustic features from voice recordings to identify benign and malignant vocal cord lesions noninvasively. Derived from the Bridge2AI-Voice...
Fundraising for AI-Driven Cell Modeling Surges
Biotech startup Tahoe Therapeutics raised $30 million to develop AI models of living human cells, contributing to efforts to sequence over a billion cells for drug discovery applications. Despite...
FDA Approves Boehringer’s Oral Lung Cancer Drug Hernexeos
Boehringer Ingelheim received accelerated FDA approval for Hernexeos (zongertinib), the first oral HER2-targeted therapy authorized for patients with non-small-cell lung cancer harboring HER2...
Vinay Prasad Returns as FDA CBER Director Amidst Industry Reactions
Vinay Prasad was reinstated as director of the FDA’s Center for Biologics Evaluation and Research (CBER) just two weeks after an ouster influenced by political pressure. The FDA commissioner...
Breakthrough in Mitochondria-Targeted Neurodegeneration Therapy
Researchers at Inserm and Université de Bordeaux developed mitoDREADD-Gs, a designer receptor targeting mitochondria to enhance energy production and reverse cognitive impairments in Alzheimer’s...
Boston Life Sciences Market Faces Historic Vacancy Amid Funding Slump
The Boston metro area’s life sciences real estate market has reached unprecedented vacancy rates, with 17 million square feet of available lab and office space and a 29.7% overall availability...
FDA Accelerates First Oral HER2 Therapy in Lung Cancer
Boehringer Ingelheim secured accelerated FDA approval for Hernexeos (zongertinib), the first oral HER2-targeted treatment for advanced non-small cell lung cancer (NSCLC) harboring activating HER2...
IO Biotech’s Melanoma Vaccine Misses Endpoint Narrowly, Eyes FDA Submission
IO Biotech’s off-the-shelf therapeutic cancer vaccine, Cylembio, narrowly missed statistical significance in its Phase 3 melanoma trial when combined with Merck's Keytruda, despite showing a 23%...
Novartis Scores Dual Phase 3 Wins in Sjögren’s Syndrome Trials
Novartis announced successful Phase 3 trial outcomes for ianalumab, a B-cell targeting antibody showing statistically significant improvements in disease activity for Sjögren’s syndrome patients....